Skip to main content
Premium Trial:

Request an Annual Quote

BioDot to Co-market Quantiscientifics Microarray System

NEW YORK (GenomeWeb News) – Privately held Quantiscientifics today said that BioDot will co-market and sell its A2 MicroArray System.

The A2 system allows for multiplexing in a 96-well plate format. The system was initially developed at Beckman Coulter and enables multiplexing of antibodies, peptides, antigens, and biomarkers.

Irvine, Calif.-based Quantiscientifics said that key applications for the system include multiplex ELISAs for cytokine detection, allergy testing, autoimmune disease, vaccines, and biomarker validation.

BioDot, also based in Irvine, sells products for the research and diagnostics markets including biochips, biosensors, lateral flow immunoassays, and liquid despensers.

Financial and others terms of the agreement were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.